Thomas Powles explains why the interim results of the NORSE trial of first-line cetrelimab plus erdafitinib in FGFR-altered advanced urothelial cancer not only justify its continuance, but also point to the need for larger studies of the combination in this setting (2:23).
This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany